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Introduction
Hematopoietic cell differentiation is thought to be achieved through promoting proliferation and survival of particular progenitors by hematopoietic growth factors and through differentiation by stochastic and/or hierarchical programmed cascades of the expression of several tissue-specific transcription factors.
1,2 During these differentiation processes, however, cells with accidental inappropriate expression of the genes that control cell proliferation and/or differentiation might be eliminated by apoptosis, otherwise the cells could be harmful to the host in some cases. This hypothesis is supported by the experimental facts that ectopic or inappropriate overexpression of such transcription factors often triggers off development of malignant tumors 3, 4 and that most of them are also implicated in the process of apoptotic cell death. 5 Therefore, the molecular events of cell differentiation, proliferation and apoptosis are tightly linked and the pathways of these processes seem to sometimes, if not always, be overlapping to some degree. A typical example has been documented in the c-myc oncogene. In various types of normal cells, c-Myc activates transcription by binding to 5'-CACGTG-3' sequences as a heterodimer with its partner, Max, and acts as a key regulator of cell proliferation. 6 Deregulated expression of the c-myc gene is implicated in neoplastic transformation of several hematopoietic progenitor cells by promoting cell proliferation and blocking cell differentiation. 7 Although ectopic expression of c-Myc is sufficient to induce cell cycle entry, overexpression of the c-myc gene induces apoptosis under serum-starved conditions. 8 In the course of the studies on the role of oncogenes in cell growth and differentiation in hematopoietic cells, we found that overexpression of the PU.1 gene, a member of the ets oncogene family, induces growth inhibition and apoptosis in murine erythroleukemia (MEL) cells under particular circumstances. In this review, we describe the functional role of PU.1 in normal hematopoiesis, and discuss involvement of PU.1 in erythroid differentiation, cell proliferation and apoptosis in murine erythroleukemia (MEL) cells focusing primarily on the data of our recent work. member of Ets family transcription factors binding to the 5'-GGAA-3' core purine-rich sequences as a monomer via a highly conserved *85-residue DNA binding domain termed the Ets domain. 16, 17 The molecular size of PU.1 is 4.2 kDa consisting of 272 amino acids (a.a.). The activation domain of PU.1 is located at the N-terminus (a.a. 7 ± 100) followed by a potentially protease-sensitive PEST domain (a.a. 118 ± 160) with a phosphorylation site (Ser 148) and the Ets DNA binding domain (a.a. 168 ± 255) forming an winged helix ± turn ± helix (wHTH) motif at the C-terminus. 18 PU.1-deficient (PU.1 7/7 ) mice exhibit defects in the development of B cells, macrophages and neutrophils, although the generation of erythroid and megakaryocytic cells is intact. 19, 20 PU.1 7/7 hematopoietic progenitors fail to express the IL-7 receptor whose signaling is probably required for Pax-5 expression. Thus, the block of B cell development caused by the PU.1 mutation may be due to the combined defects in IL-7 signaling as well as the failure to induce expression of Pax-5.
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PU.1 7/7 embryonic stem (ES) cells also fail to differentiate into macrophages in vitro. 22 This failure is complemented by a PU.1 transgene, providing evidence that PU.1 promotes macrophage differentiation from pluripotent ES cells.
23 PU.1 functions in an exclusively cell ± autonomous manner to regulate development of lymphoid and myeloid cells. 24 Furthermore, the knockout mice also show a hallmark of osteopetrosis, a sclerotic bone disease, with the absence of myeloid-derived osteoclasts as well as macrophages. 25 Thus, PU.1 appears to be a master regulator, critical for development of a common progenitor for the lymphoidmyeloid cell lineages in the hematopoietic system. It binds to the corresponding sequences in the promoters and enhancers of many B cell-and myeloid-specific genes. The major target genes for PU.1. are listed in Table 1 .
In pre-B and B cells, PU.1 regulates the immunoglobulin genes. 26 A minimal domain of the intronic enhancer of the immunoglobulin m heavy-chain (IgH) gene is composed of the mA, mE3 and mB that bind Ets-1, TFE3/AML1 and PU.1, respectively. 27 In the Igk 3' enhancer, PU.1 apparently can activate transcription by playing an architectural role in interaction with other transcription factors such as c-Fos, cJun and ATF-1. 28 The PU.1-binding site in the enhancer is also responsible for the negative regulation of tissue (T/B cell)-and the stage (pro-B/pre-B cell)-specific Vk ± Jk joining. 29 To activate the Igk and l enhancer elements, PU.1 has to form a ternary complex with a lymphoidrestricted interferon regulatory factor, IRF-4/NF-EM5/ Pip (PU.1 interaction partner) which contacts DNA on nucleotides immediately adjacent to the PU.1 binding site. 30 The formation of the PU.1 ± Pip ± DNA complex requires the phosphorylation of Ser 148 in the PEST domain of PU.1 by Caseine Kinase II.
31 Interaction of PU.1 with Pip has also been reported in B-lineage-specific expression of the CD20 promoter in co-operation with members of the basic helix ± loop ± helix zipper (bHLHZ) family of transcription factors.
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In myeloid cells, PU.1 upregulates various myeloidspecific genes such as the M-CSF receptor (c-fms), G-CSF receptor, GM-CSF receptor, FcgR, CD11b, CD18, myeloperoxidase (MPO) and c-fes genes. 2, 33 Thus, failure in the development of myeloid lineages during fetal liver hematopoiesis in PU.1-deficient mice 19, 20 could be partly due to absence of expression of GM-CSF receptors. However, this is not true, since early myeloid genes such as GM-CSFR, G-CSFR and MPO are expressed in PU.1 7/7 embryos and differentiated PU.1 7/7 ES cells.
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In spite of expression of GM-and G-CSFR, PU.1
myeloid progenitors fail to respond to GM-and G-CSF, although the unresponsiveness to G-CSF is bypassed by signaling with IL-3 in vitro. 34 The expression of genes associated with terminal myeloid differentiation such as M-CSFR and CD11b is eliminated in differentiated PU.1 7/7 ES cells. PU.1 7/7 mice develop neutrophils but PU.1-deficient neutrophils fail to respond to chemokines, do not generate superoxide ions, and are ineffective at bacterial + cells in vitro, CFU-GM (granulocyte/macrophage ± colony-forming unit) and BFU-E (erythroid burst-forming unit) formation was extensively decreased. Enforced expression of PU.1 in multipotent hematopoietic progenitors induces myeloid lineage commitment probably by suppression of a master regulator of nonmyeloid genes. 39 These data suggest that PU.1 is essential during the early phases of both myeloid and erythroid hematopoietic cell commitment.
Analyses of the murine and human PU.1 promoters revealed that PU.1 itself activates its own promoter in an autoregulatory loop.
40,41 Furthermore, our previous work in somatic cell hybrids suggest that PU.1 expression is programmed to be turned on in specific hematopoietic lineages by release from negative regulation during embryonic cell differentiation. 42 Full characterization of the transcriptional cascades involved in regulation of PU.1 gene expression during development remains to be determined.
Deregulated expression of PU.1 in murine erythroleukemia cells
As described above, PU.1 is highly expressed in the normal course of B cell and macrophage differentiation. In contrast, the level of PU.1 expression is not so high in normal erythroid cells and appears to be downregulated in erythropoiesis. Thus, by accident, deregulated expression of PU.1 in erythroid cells could possibly result in abnormal cell proliferation and differentiation. Indeed, activation of the PU.1 gene, which is identical to the Spi-1 (spleen focusforming virus proviral integration-1) gene located near the common proviral integration site in MEL cells, 43,44 is believed to be an important step of murine erthroleukemogenesis induced by inoculation of Friend virus in mice. 45 Furthermore, infection of mouse long-term bone marrow cultures with a PU.1/Spi-1-encoding retrovirus resulted in polyclonal expansion of immortalized erythroblasts, although the resulting cell lines still required erythropoietin (Epo) and bone marrow stromal cells for their survival and proliferation. 46 More direct evidence for deregulated expression of the PU.1 gene in leukemogenesis was provided from the experimental fact that transgenic mice homozygous for the PU.1/Spi-1 gene developed a multistep erythroleukemia with hepato-splenomegaly early after birth. 47 
PU.1 in erythroid differentiation
Established MEL cells are clonogenic in vitro and tumorigenic in vivo but still have a potential to differentiate into erythrocytelike cells expressing the b-globin gene when treated with dimethyl-sulfoxide (DMSO) or N, N' -hexamethylene-bisacetamide (HMBA) in vitro.
48 It is well known that expression of the c-myc and c-myb oncogenes is downregulated during terminal erythroid differentiation and overexpression of these genes inhibits cell differentiation of MEL cells.
49,50 Expression of the PU.1 gene is also found to be decreased during MEL cell differentiation. 51 Our results clarified the role of PU.1 in erythroid differentiation by showing that introduction of a zincinducible expression plasmid of PU.1 into MEL cells markedly inhibited induction of the b-globin gene after treatment with DMSO and ZnCl 2 .
9 A similar result was obtained independently by another group using a constitutive expression vector.
52 Thus, overexpression of PU.1 inhibits differentiation of MEL cells, suggesting that downregulation of the PU.1 gene is prerequisite for terminal erythroid differentiation. In other words, PU.1 acts as an oncogene to inhibit terminal differentiation in erythroid cells.
Interestingly, the differentiation block was also observed in MEL cells transfected with PU.1 mutants with a deletion in the activation domain but not with a deletion in the Ets domain. 9 Thus, the activation domain of PU.1 appeared to be dispensable for PU.1-induced differentiation block in MEL cells. Similar results have been reported in the block of TPA-induced monocytic differentiation in v-myb transformed monoblasts, where overexpression of the mutant forms of c-Myb with deleted activation domains can by-pass cell differentiation and cell cycle arrest as effectively as the wild-type. 53 Furthermore, deletion of the acidic transactivation domain of PU.1 does not affect its ability to promote macrophage development, suggesting that protein-protein interaction may be important during macrophage development. 54 Transcriptional activities of these factors may not be required to inhibit cell differentiation.
PU.1 binds to the DNase I-hypersensitive intervening sequence 2 in the mouse b-globin gene to change chromatin structure. 55 The transferrin receptor is critical for erythroid differentiation and its promoter is activated by Ets-1.
56 A competitive action of PU.1 against other Ets family proteins on the promoter binding sites of such erythroid-specific genes could be one reason for PU.1-induced differentiation block in MEL cells. Enhanced expression of exogenous retinoic acid receptor alpha (RARa) and thyroid hormone receptor alpha (TRa/c-erbA) in erythroblasts rendered them susptible to modulation of erythroid differentiation by RA and T3. 57 Functional interference between PU.1 and steroid hormone or vitamin receptors including RARa and TRa has been found in reporter assays.
58 Thus, negative cross-talk between PU.1 and nuclear hormone receptors acting in the erythroid differentiation pathway seems to be one reason for differentiation block. Interaction of PU.1 with coactivator CREB-binding protein (CBP) is a likely molecular mechanism involved in such negative cross-talk, as discussed later.
PU.1 in growth control
Since the PU.1 gene is an oncogene and it immortalizes erythroblasts, 46 it has been speculated that overexpression of PU.1 might promote proliferation of cells. When PU.1/Spi-1 gene expression in MEL cells was inhibited by using relatively high doses of antisense oligonucleotides, proliferation and cloning efficiency of the cells were shown to be decreased with about 40% inhibition. 59 On the contrary, when the PU.1 level was increased by transfection of MEL cells with a zincinducible PU.1-expression vector, cell growth was unexpectedly reduced in the presence of ZnCl 2 . 9 The growth inhibition appears not to be due to the combined effect of ZnCl 2 , since growth reduction has also been reported in MEL cells transfected with a constitutive PU.1-expression vector. 52 Similarly, ectopic overexpression of PU.1 in K562, a human myeloid leukemic cell line, significantly reduces the growth rate, with inhibition of erythroid differentiation and promotion of monocytic differentiation. 60 Although we do not know the reason for these seemingly paradoxical results at present, the expression level of the gene may be critical for these effects. A moderate level of PU.1 expression might be necessary for transformation and deregulated proliferation of proerythroblasts, while a high level of expression may be rather toxic and induce apoptosis as mentioned in the next section. Given the fact that PU.1 transactivates tissue-specific genes necessary for differentiation of B cells and macrophages, it may be reasonable for PU.1 to inhibit cell proliferation in the terminal stages of these cell lineages. Thus, it is evident that PU.1 induces growth arrest rather than cell proliferation in some cases. Growth arrest induced by overexpression of PU.1 in MEL cells could be partly explained by decrease in c-myc mRNA and its corresponding protein expression levels. 10 The c-myc promoter (7138 to +517) was found to be a target of downregulation by PU.1 in a dose-dependent manner by luciferase assay (Kihara-Negishi et al, in preparation). Moreover, the activity of the c-myb promoter (7197 to +204) was also found to be decreased in MEL cells in a dose dependent manner when a PU.1-expression vector was cotransfected, consistent with the results reported by others. 61 Induction of p21 Cip1 gene expression and temporal downregulation of c-myc and c-myb gene expression by treatment of MEL cells with DMSO 62 could further augment growth inhibition induced by PU.1 overexpression alone. The possible involvement of c-myc and c-myb in PU.1-induced growth arrest does not exclude the possibility that other transcription factors such as members of the Fos/Jun family are also involved in this effect, since Ets family proteins and AP-1 are critical nuclear targets of Ras-MAP-kinase signaling pathway for cell proliferation.
63,64 The effect of overexpression of PU.1 on Fos/Jun family expression in MEL cells is so far unknown. Direct physical interactions between Ets family and Jun family transcription factors have been reported 65 and Fos/Jun family are implicated in cell differentiation, proliferation and apoptosis in several hematopoietic cells. 66, 67 
PU.1 in apoptosis
The growth of MEL cells transfected with a zinc inducible PU.1-expression vector was markedly reduced when the cells were treated with DMSO in addition to ZnCl 2 and apoptotic cell death was subsequently observed by 48 h after the treatment. 9 FACS analyses revealed that accumulation of cells in G0/G1 phase preceded the onset of apoptosis and the apoptosis occurs in G0/G1 through S-phases but not in G2-through M-phases. 10 A remarkable decrease in c-myc and bcl-2 gene expression was noticed in PU.1-transfectants treated with DMSO and ZnCl 2 , while no significant differences were observed in bcl-X L , bax, p21
Cip1 , p53, Fas and Fas-ligand gene expression as compared with their expression kinetics in control cells under the same conditions. 10 The reduction of the c-Myc and Bcl-2 protein levels preceded the induction of apoptosis. PU.1-induced apoptosis was prevented in cells cultured in 30% serum, where a decrease in c-myc and bcl-2 gene expression was not observed. Thus, high concentrations of serum in culture rescues MEL cells from PU.1-induced apoptosis probably through maintaining the expression levels of the c-myc and bcl-2 genes. In support of this idea, enforced expression of the c-myc and bcl-2 genes in PU.1-transfected cells attenuated apoptosis, if not completely. 10 In contrast to PU.1-induced differentiation block, PU.1-induced growth arrest and apoptosis required both the activation and the Ets domain of PU.1. This is similar to c-Myc-induced cell proliferation and apoptosis, in which all of the transactivation domain, the DNA-binding domain and the dimerization domain of c-Myc are necessary. 68 Thus, transcriptional activation of certain genes by PU.1 seems to be important for growth arrest and apoptosis. These results also indicate that there was no association between competence for induction of cell differentiation and ability to induce apoptosis by overexpression of PU.1 in MEL cells. Collectively, overexpression of PU.1 in MEL cells induces apoptosis by a p53-or Fas-independent pathway which is probably mediated by downregulation of bcl-2 and/or c-myc gene expression.
Induction of PU.1-induced growth arrest and apoptosis in MEL cells appeared to be closely linked, in contrast with the dissociation between PU.1 induced differentiation block and growth arrest or apoptosis. 9 Overexpression of PU.1, or treatment with DMSO alone, induced moderate and slight inhibition of proliferation in MEL cells, and both were needed to induce growth arrest and apoptosis. Severe growth inhibition may be a trigger for PU.1-induced apoptosis. Apoptosis may be induced by mitotic catastrophe due to insufficient sets of effectors for cell cycle progression. 69 c-Myc-/c-Myb-induced apoptosis c-Myc has been shown to harbor both mitogenic and apoptotic properties. 70 Involvement of c-Myc in the induction of apoptosis has been reported in several cell systems. For example, inappropriate overexpression of c-myc following deprivation of growth factors, promotes apoptosis in myeloid progenitor cells 71 and in fibroblasts. 8 T-cell receptor-mediated apoptosis in immature T cells is also associated with induction of c-myc expression and is abrogated by addition of c-myc antisense oligonucleotides to the cells. 72 In these cases, overexpression of c-Myc is a trigger for the onset of apoptosis. In contrast to these reports, the recent growing evidence suggests that a drop in c-myc expression induces apoptosis in hematopoietic cell systems. For example, treatment of B-cell lines with anti-IgM antiserum or TGFb results in a dramatic decline in c-myc expression due to a reduction of DNA binding by NFkB/Rel family transcription factors to its promoter, and subsequently leads to growth inhibition and activation of apoptosis of the cells. 73, 74 Recently, it has reported that NFkB/Rel family transcription factors positively regulate expression of the prosurvival bcl-2 homolog A1/bfl-1 gene 75 that is critical for the control of cell survival during lymphocyte activation. 76 Ectopic expression of Blimp-1, a plasmacytoma repressor factor, represses endogenous c-Myc by binding to the c-myc promoter and causes apoptosis in B cells. 77 This apoptosis can be partially overcome by ectopic expression of c-Myc. Furthermore, suppression of c-myc is also a critical step in glucocorticoid-induced apoptosis in a T cell leukemia line. 78 In these cases, an extensive drop in c-Myc expression is a trigger of onset of apoptosis. Downregulation of c-Myc expression in PU.1-induced apoptosis falls in this category. Expression of c-myc is generally consistent with the proliferative rate of cells and it is activated by stimulation by mitogens or growth factors. Erythropoietin (Epo) regulates growth and survival of erythroid cells by increasing c-myc transcripts by a protein kinase C-dependent pathway. 79 Proliferation of Friend virus-infected pre-leukemic proerythroblasts at an early stage is dependent on Epo, and depletion of the factor leads to apoptotic cell death. 46 Since growth of the MEL cells we used is Epo-independent, and there was no change in Epo receptor gene expression even after PU.1 overexpression (Kondoh et al, unpublished observations), continuous activation of the c-myc gene must have occurred without any stimulation of Epo in this cell line. Thus, downregulation of c-myc expression in Epo-independent line may lead to a situation similar to Epo deprivation in Epodependent cell lines.
c-Myb transactivates the promoters of the c-myc and bcl-2 genes in various hematopoietic cell lines, 80, 81 and downregulation of c-myb also leads to apoptosis in several systems. The dramatic growth arrest and reduction of cell number in c-myb antisense-transfected neuroblastoma cells has been reported to be due to the induction of apoptosis 82 and downregulation of c-myb is associated with apoptosis in T cells. 83 As previously mentioned, we found that the activities of the c-myc and c-myb promoters were negatively regulated by overexpression of PU.1 in MEL cells. Since there are several putative Ets-binding sites (EBS) in the c-myc and c-myb promoters 84 and in the bcl-2 promoter, 85 a competitive action of PU.1 against Ets-1/Ets-2 at the EBS might influence promoter activities. Experiments are being performed in our laboratory to elucidate the precise molecular mechanisms of the suppression of these promoter activities.
GATA-1 and apoptosis
Several hematopoietic transcription factors, including GATA-1, NF-E2, SCL/Tal-1, EKLF and LOM2/Rnbt2, are required for erythroid development and differentiation. 1 Targeted disruption of the GATA-1 gene leads to impairment of erythropoiesis in mice. 86 GATA-1 negative embryonic stem (ES) cells fail to differentiate into mature erythroid cells and GATA-1 negative erythroid precursors undergo apoptosis. 87 These reports suggest that survival as well as differentiation of erythroid cells is maintained by hematopoietic transcription factors. 1 We found that GATA-1-DNA but not NF-E2-DNA complex formation as judged by EMSA was markedly reduced in PU.1-transfected cells by 32 h after treatment with DMSO and ZnCl 2 just when apoptosis started, though a prominent GATA-1 signal was detected in Northern and Western blot analyses in the transfectants comparable to that in mock-transfectants under the same conditions. 12 The reduced DNA binding of GATA-1 in PU.1-transfectants undergoing apoptosis was not due to a decreased level nor a change in subcellular localization of GATA-1 protein as found in avian erythroid differentiation. 88 The reduced DNAbinding activity of GATA-1 was restored when PU.1-induced apoptosis was counteracted by adding 30% serum to the culture medium. Treatment of nuclear extracts from MEL cells undergoing apoptosis with alkaline phosphatase did not restore the DNA-binding activity of GATA-1, consistent with the report that the phosphorylation state of GATA-1 does not significantly influence its DNA-binding activity. 89 Interestingly, the DNA-binding activity of GATA-1 in parental MEL cells was abolished by premixing with the same amounts of nuclear extracts from PU.1-transfected MEL cells but not from the parental cells cultured with DMSO and ZnCl 2 for 48 h. Thus, an inhibitory factor(s) which interacts with GATA-1 and prevents it from binding to DNA might be induced or become active in the apoptotic process. In line with this, it has been shown that estrogeninduced apoptosis of MEL cells is accompanied by inhibition of GATA-1 activity. 90 Downregulation of DLX-7 homeobox gene expression results in a reduction of GATA-1 and c-myc mRNA levels, with an accompanying induction of apoptosis in a human myeloid leukemic cell line K562. 91 Thus, PU.1 may participate in cell proliferation and apoptosis by modulating other transcription factors that play key roles in apoptosis.
Interaction of PU.1 with other proteins
PU.1 may indirectly affect expression of several genes critical for differentiation, proliferation and apoptosis by interacting with other proteins, since the activation domain at the Nterminus of PU.1 has been shown to interact in vitro with the conserved C-terminal domain of the basal transcription factor TFIID and the`pocket' domain of the tumor suppressor retinoblastoma (Rb) protein. 92 Furthermore, the C-terminal region of PU.1 has been reported to interact with the leucine zipper transcription factor NF-IL6b (C/EBPd), the DNAbinding protein HMG I/Y, the multi-functional phosphatase MKP-1 and the chaperone protein HSP 90.
93 PU.1 also binds to the potential splicing factors p54 nrb (nuclear RNA-binding protein 54 kDa) and TLS (translocated in liposarcoma)/ FUS, a gene related to EWS (Ewing's sarcoma). 94, 95 We recently found that a portion of the transcriptional activation domain (a.a. 74 ± 122) of PU.1 directly interacted with the region spanning residues 1283 ± 1915 of the CREB binding protein (CBP), overlapping with the adenovirus E1A-binding site. 13 CBP and the related protein p300 have been reported to interact with a variety of transcription factors, including CREB, AP-1 (Fos/Jun), c-Myb, nuclear hormone receptors (NHRs), STATs, NFkB, E2F-1 and p53, as well as viral oncoproteins like E1A and SV40 large Tantigen. 96 ,97 p300/CBP serves as a transcriptional adaptor for several transcription factors 98 by direct bridging between basal transcription factors and several sequence-specific transcriptional activators. p300/CBP itself and the cellular p300/CBP associated factor (P/CAF) possess intrinsic histone acetyltransferase (HAT) activities. 99, 100 Given the good correlation between acetylation of core histones and transcriptional activity, it is speculated that the HAT activity of P/CAF and/or p300/CBP is responsible for regulation of chromatin configuration. 101 Beside histones, p300/CBP can directly modify the C-terminal domain of the p53 tumor suppressor protein and the DNA binding domain of the erythroid transcription factor GATA-1 by acetylation to stimulate their DNA binding activities. 102, 103 It has been reported that CBP is required for differentiation of muscle and B cells, and inhibition of CBP function by E1A viral oncoprotein blocks cell differentiation. 104 Furthermore, CBP has been reported recently to interact with two other hematopoietic transcription factors important for erythroid differentiation, Ets-1 99 and GATA-1 90 , through the region overlapping with the PU.1 binding site. Since CBP is a shared coactivator for several transcription factors within cells, 105 functional interference between AP-1 and NHRs has been proposed to be a result of competition for limiting amounts of CBP in cells. 106 By analogy to this, it is tempting to speculate that sequestration of a limiting amount of CBP by a large amount of PU.1 could decrease the interactions of CBP with erythroid differentiation-and/or survival-promoting transcription factors, such as GATA-1, 107 Ets-1 108, 56 and NHRs, 109 in PU.1-overexpressing MEL cells, and subsequently lead to erythroid differentiation block, growth arrest and apoptosis. Indeed, a mutual antagonistic effect has been reported between PU.1 and NHRs, although there is no direct physical contact between two. 58 We are currently in the process of substantiating the involvement of CBP in cell differentiation, proliferation and apoptosis of MEL cells.
Concluding remarks
In this review, we have briefly summarized the functional role of PU.1 in normal B and myeloid cell proliferation and differentiation. We have also described how overexpression of PU.1 in murine erythroleukemia (MEL) cells in conjunction with DMSO induces differentiation block, growth arrest and apoptosis, and have discussed possible molecular mechanisms for these effects. The precise molecular mechanisms of the PU.1-induced cellular effects in MEL cells are still obscure. However, a simple scheme of the pathways and relevant molecules involved in PU.1-induced differentiation block, growth arrest and apoptosis as understood at present is illustrated in Figure  1 .
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It is not so surprising that PU.1 induces apoptotic cell death, considering that many oncogenes and tumor suppressor genes are involved in apoptosis as well as malignant transformation in hematopoietic cells. 5 The c-myc oncogene can induce both proliferation and apoptosis but its net effect depends upon the status of other components within the cell. This is also true for the ras oncogene. Activated Ras induces growth arrest rather than cell proliferation by inducing cyclin-dependent kinase (CDK) inhibitor p21
Cip1 , when the signal through Ras-related GTPase Rho is inhibited. On the other hand, when Rho is active, induction of p21
Cip1 by Ras is suppressed and Ras induces DNA synthesis. 110 Although over-expression of PU.1 induced growth inhibition in MEL cells, it did not induce growth inhibition in a fibrosarcoma cell line grown in liquid culture, 11 suggesting that PU.1-induced growth arrest and apoptosis might be cell type-specific. Alternatively, PU.1 may exert different effects in different cellular states, which may explain why high levels of expression of PU.1 are not toxic in normal B cells and macrophages/ neutrophils.
More complicated is the fact that both overexpression and downregulation of the c-myc gene can induce apoptosis in cells. This may suggest that not only cellular state and cell background, but also expression levels of the oncogenes, influence the net effects. The effects of c-Myc on other factors regulating the cell cycle and apoptosis may be different with low and high dose expression. In this context, it has been reported that moderate Raf activity induces DNA synthesis by inducing cyclin D expression, while a high-intensity Raf signal causes cell cycle arrest through induction of p21 INK4a . 112 Similarly, whether PU.1 induces growth arrest or not might be decided by its expression level in cells.
Apoptosis is believed to play an important role in eliminating unwanted cells which have a potential to easily become malignant cells. In this sense, apoptosis induced by overexpression of oncogenes might be a cellular failsafe system to prevent malignant transformation as well as apoptosis induced by tumor suppressor genes. 113 Cancer cells seem to arise by sneaking through such a subtle balance in cells, where both overexpression and low dose expression of oncogenes are not effective to transform cells. This may explain the seemingly discrepant cellular effects of PU.1 on cell transformation, growth arrest and apoptosis. The tumor suppressor gene p53 is believed to be a safe guardian in development of mouse erythroleukemias 45 as well as most human tumors. 114 This notion is supported by the facts that the p53 gene is often inactivated by viral integration or mutation in most MEL cells 115 and that introduction of the wild-type p53 gene into MEL cells induces apoptosis. 116 A mutated p53 gene in tumor cells facilitates escape from apoptosis. In our study, however, accumulation of p53 was not observed in PU.1-overexpressing MEL cells, indicating that PU.1-induced apoptosis is p53-independent. 10 Other Ets family members are also implicated in cell proliferation and apoptosis. Fli-1 is a member of the Ets family of transcription factors also implicated in MEL genesis, 117 and transcription of the Fli-1 gene is positively regulated by PU.1. 118 The Fli-1 gene is rearranged with the EWS gene in the development of human Ewing sarcomas by specific chromosomal translocation. 119 Expression of Fli-1 as well as EWS-Fli-1 promotes cell proliferation and inhibits apoptosis. 120 Introduction of a retroviral construct expressing Fli-1 into K562 cells reduces the growth rate of the cells and causes induction of megakaryocytic and erythroid differentiation. 121 Furthermore, overexpression of Fli-1 in MEL cells did not induce significant growth arrest and apoptosis (Matsumoto et al, in preparation), suggesting that PU.1 and Fli-1 exert different cellular effects in spite of their involvement in MEL genesis, and that the PU.1-induced cellular effects mentioned above are not mediated through Fli-1. Ectopic expression of Ets-1 reduces tumorigenicity of human colon cancer cell lines, due to its ability to induce apoptosis. 122 These results suggest that the ets-family oncogenes are involved not only in important steps of cell differentiation and proliferation but also in antiproliferative and apoptotic processes under certain circumstances.
Finally, our results, taken together with other reports, support the complicated but interesting notion that oncogenes sometimes act like tumor suppressor genes 123 or induce cell differentiation, 124 
